



Esperion Therapeutics, Inc.
 Investor Relations Department
 3891 Ranchero Drive
 Suite 150
 Ann Arbor, MI 48108
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: ESPR


Last Trade:	38.32
Trade Time:	4:00 PM ET May 23, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	30.95 - 82.68
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 23, 2018
[Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint](#)
- May 22, 2018
[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)
- May 10, 2018
[Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference](#)
- May 4, 2018
[Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference](#)
- May 2, 2018
[Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 20, 2018
[Annual Report \(10-K\)](#)
- Apr 13, 2018
[Proxy Statement \(DEF 14A\)](#)
- May 2, 2018
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017
[Quarterly Report \(10-Q\)](#)